Sesen Bio, Inc. (SESN)
| Previous Close | 0.7313 |
| Open | 0.7330 |
| Bid | 0.7344 x 1100 |
| Ask | 0.7396 x 1000 |
| Day's Range | 0.7260 - 0.7498 |
| 52 Week Range | 0.3650 - 6.0400 |
| Volume | |
| Avg. Volume | 4,296,982 |
| Market Cap | 147.304M |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | 2.24 |
| EPS (TTM) | 0.3300 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.56 |
- Business Wire
Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update
CAMBRIDGE, Mass., August 08, 2022--Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company paused clinical development of its lead asset, Vicineum™ for the treatment of non-muscle invasive bladder cancer (NMIBC), and turned its primary focus to the assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022.
- Zacks
What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?
Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.
- Zacks
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.
